At a glance
- Originator Yamanouchi
- Class Antiasthmatics; Antiplatelets
- Mechanism of Action Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
- Discontinued Asthma
Most Recent Events
- 20 May 1996 Discontinued-II for Asthma in Japan (PO)
- 17 Oct 1994 Preclinical development for Septic shock in Japan (Unknown route)
- 17 Oct 1994 Preclinical development for Thrombosis in Japan (Unknown route)